Inspire(US:INSP) Globenewswire·2026-01-04 17:00Core Viewpoint - A securities class action lawsuit has been filed against Inspire Medical Systems, Inc. (NYSE: INSP) for allegedly misleading investors about operational failures related to the launch of its Inspire V device for obstructive sleep apnea [1][3]. Group 1: Allegations and Impact - The lawsuit claims that Inspire Medical assured investors of its "operational readiness" for the Inspire V launch, which was later revealed to be false due to undisclosed operational issues [3][4]. - Key operational failures included delays in Medicare claims processing software updates, which did not take effect until July 1, 2025, preventing implanting centers from billing for procedures [4]. - An excess inventory of the older Inspire IV device created a channel glut, negatively impacting demand for the new Inspire V product and necessitating an inventory "burn down" [4]. - Many treatment centers had not completed essential training for the new device, contributing to the launch's failure [4]. - As a result of these issues, Inspire Medical slashed its 2025 EPS guidance by over 80%, leading to a $42.04 per share drop and a 32.4% decline in stock value [4]. Group 2: Legal Actions and Investor Guidance - Investors who purchased Inspire Medical securities between August 6, 2024, and August 4, 2025, are encouraged to contact Hagens Berman to discuss their legal rights before the January 5, 2026, Lead Plaintiff Deadline [2][3]. - Hagens Berman is focusing on the alleged concealment of critical operational failures and is inviting investors to share information that may assist in the investigation [5].